- Home
- AEVA vs ADAP Comparison
AEVA vs ADAP Comparison
Compare AEVA & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- ADAP
- Stock Information
- Founded
- AEVA 2019
- ADAP 2008
- Country
- AEVA United States
- ADAP United Kingdom
- Employees
- AEVA N/A
- ADAP N/A
- Industry
- AEVA Auto Parts:O.E.M.
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- ADAP Health Care
- Exchange
- AEVA Nasdaq
- ADAP Nasdaq
- Market Cap
- AEVA 201.0M
- ADAP 212.3M
- IPO Year
- AEVA N/A
- ADAP 2015
- Fundamental
- Price
- AEVA $3.78
- ADAP $0.64
- Analyst Decision
- AEVA Buy
- ADAP Strong Buy
- Analyst Count
- AEVA 5
- ADAP 4
- Target Price
- AEVA $10.53
- ADAP $3.16
- AVG Volume (30 Days)
- AEVA 342.6K
- ADAP 2.4M
- Earning Date
- AEVA 11-06-2024
- ADAP 11-13-2024
- Dividend Yield
- AEVA N/A
- ADAP N/A
- EPS Growth
- AEVA N/A
- ADAP N/A
- EPS
- AEVA N/A
- ADAP N/A
- Revenue
- AEVA $7,980,000.00
- ADAP $175,041,000.00
- Revenue This Year
- AEVA $110.92
- ADAP $180.15
- Revenue Next Year
- AEVA $108.75
- ADAP N/A
- P/E Ratio
- AEVA N/A
- ADAP N/A
- Revenue Growth
- AEVA 176.22
- ADAP 146.27
- 52 Week Low
- AEVA $2.20
- ADAP $0.42
- 52 Week High
- AEVA $7.25
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- AEVA 49.12
- ADAP 36.20
- Support Level
- AEVA $3.32
- ADAP $0.57
- Resistance Level
- AEVA $3.81
- ADAP $0.71
- Average True Range (ATR)
- AEVA 0.30
- ADAP 0.07
- MACD
- AEVA -0.08
- ADAP -0.01
- Stochastic Oscillator
- AEVA 36.80
- ADAP 22.70
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.